Zanidatamab (ZW25)

About Zymeworks

Zymeworks Inc. is a global biotechnology company committed to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. Its core expertise lies in protein engineering, with platforms like Azymetric™ for bispecific antibodies and ZymeLink™ for antibody-drug conjugates enabling a robust pipeline of oncology candidates. The company leverages a dual strategy of advancing its own clinical programs, such as zanidatamab, while entering into significant collaborations with major pharmaceutical firms to broaden the impact of its technology.

About Zymeworks

Zymeworks Inc. is a global biotechnology company committed to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. Its core expertise lies in protein engineering, with platforms like Azymetric™ for bispecific antibodies and ZymeLink™ for antibody-drug conjugates enabling a robust pipeline of oncology candidates. The company leverages a dual strategy of advancing its own clinical programs, such as zanidatamab, while entering into significant collaborations with major pharmaceutical firms to broaden the impact of its technology.

Therapeutic Areas